Literature DB >> 16739187

Influence of clinical features on the health status of patients with limited cutaneous systemic sclerosis.

Angela E Gliddon1, Caroline J Doré, Peter J Maddison.   

Abstract

OBJECTIVE: To determine the effect of limited cutaneous systemic sclerosis (lcSSc) on patients' health status, and to identify the contributions to health status of different manifestations of lcSSc.
METHODS: The Short Form 36 questionnaire was completed by 213 patients with lcSSc or Raynaud's syndrome and an antinuclear antibody typical of lcSSc as part of the baseline visit of the Quinapril in Scleroderma trial. Results were analyzed after correcting for age and sex using the Welsh Health Survey. Patients' results were related to their clinical characteristics.
RESULTS: The mean physical component score (PCS) was 44.0 (95% confidence interval [95% CI] 42.5, 45.5), which was lower than the population norm of 50, and the median mental component score (MCS) was 52.2 (95% CI 48.5, 54.3). Raynaud's disease visual analog scale (VAS) scores, lung function, the number of organ systems affected, and skin score were significantly correlated with PCS. The total score (TDS) of an SSc severity scale showed the highest correlation. The effect of lcSSc on PCS was worse in younger patients. Multiple regression including age demonstrated that Raynaud's disease severity could predict a reduction in PCS beyond that predicted by TDS. Raynaud's disease severity and duration of lcSSc were linked to low MCS. Arthritis reduced PCS and esophageal involvement reduced PCS and MCS.
CONCLUSION: Physical health status of patients with lcSSc was reduced, with 30% of the variation predicted by TDS, age, and severity of Raynaud's disease VAS. Mental health status was not reduced in this population.

Entities:  

Mesh:

Year:  2006        PMID: 16739187     DOI: 10.1002/art.21999

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  5 in total

1.  Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.

Authors:  Dinesh Khanna; Daniel E Furst; Paul Maranian; James R Seibold; Ann Impens; Maureen D Mayes; Philip J Clements; Terri Getzug; Ron D Hays
Journal:  J Rheumatol       Date:  2011-07-01       Impact factor: 4.666

Review 2.  Patient-reported outcome instruments in clinical trials of systemic sclerosis.

Authors:  John D Pauling; Joana Caetano; Corrado Campochiaro; Giacomo De Luca; Ana Maria Gheorghiu; Maria Grazia Lazzaroni; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2019-11-25

3.  Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.

Authors:  Dinesh Khanna; Ron D Hays; Paul Maranian; James R Seibold; Ann Impens; Maureen D Mayes; Philip J Clements; Terri Getzug; Nihal Fathi; Amber Bechtel; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2009-09-15

4.  Functioning and health-related quality of life in Chinese patients with systemic sclerosis: a case-control study.

Authors:  P T Chan; C C Mok; K L Chan; L Y Ho
Journal:  Clin Rheumatol       Date:  2014-02-16       Impact factor: 2.980

Review 5.  GI Manifestations With a Focus on the Esophagus: Recent Progress in Understanding Pathogenesis.

Authors:  Marie-Pier Tétreault; Peter Kahrilas
Journal:  Curr Rheumatol Rep       Date:  2019-07-03       Impact factor: 4.592

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.